Drugs / TOFOGLIFLOZIN ANHYDROUS
TOFOGLIFLOZIN ANHYDROUS
also known as
Tofogliflozin · RO4998452 · CSG452 · R-7201 · Tofogliflozin hydrate · Tofogliflozin monohydrate · Tofogliflozina · Tofogliflozine
Other / unclassified targets SLC5A2 via inhibition
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04237597 | Dec 2019 → Jan 2020 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01044017 | Dec 2009 → Aug 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00933972 | Jun 2009 → Sep 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00682097 | May 2008 → Mar 2009 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05327127 | Nov 2022 → May 2026 | metabolic dysfunction-associated steatohepatitis | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05469659 | Sep 2021 → Oct 2025 overdue | type 2 diabetes mellitus | Shinshu University | Recruiting | No outcome recorded |
| Phase 2 | NCT00800176 | Jan → Oct 2009 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02537834 | Aug 2015 → Jul 2017 | type 2 diabetes mellitus | Kowa Company, Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02201004 | Jun 2014 → Jan 2016 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT02649465 Comparator | Nov 2015 → Dec 2020 | NAFLD1 | Kanazawa University | Completed | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOFOGLIFLOZIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Known as | CSG452 | “TOFOGLIFLOZIN CSG452” NCT02201004 ↗ |
| Known as | R-7201 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Known as | RO4998452 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00800176 ↗ |
| Known as | Tofogliflozin | “tofogliflozin (20mg daily)” NCT02528019 ↗ |
| Known as | Tofogliflozin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Known as | Tofogliflozin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Known as | Tofogliflozina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Known as | Tofogliflozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110731 ↗ |
| Action | Inhibit | “sodium-glucose co-transporter-2 [SGLT2] inhibitor” PMID 28371205 ↗ Jul 2017 |
| Modality | Other / unclassified | “SGLT2 inhibitor tofogliflozin” NCT02649465 ↗ |
| Route | Oral | “Escalating oral doses” NCT00682097 ↗ |
| Target | SLC5A2 | “tofogliflozin, a selective inhibitor of Sodium-Glucose Cotransporter 2 (SGLT2)” PMID 29766812 ↗ 2019 |